Dhanuka Agritech Q1 FY27 Earnings Call — Analysis (NSE: DHANUKA)
Dhanuka Agritech reports 12.6% YoY revenue decline in Q1FY27 on monsoon deficit, cuts FY27 growth guidance to low single digits, and announces a ₹200 Cr automated formulation plant in Nagpur.
The take
Q1FY27 Revenue ₹461.93 Cr ( -12.56% YoY ) . New guidance — FY27 fy27 consolidated revenue growth small single-digit . New story: Nagpur automated formulation capacity .
Results
Revenue ₹461.93 Cr (-12.56% YoY); EBITDA ₹55.01 Cr; PAT ₹36.30 Cr; volume declined ~12.7% YoY, with herbicide sales heavily impacted by delayed and deficient monsoon.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹461.93 Cr | -12.56% | yoy · Q1FY27 · vs ₹528.29 Cr in Q1FY26 |
| EBITDA | ₹55.01 Cr | point_in_time · Q1FY27 · Q1FY27 | |
| PAT | ₹36.30 Cr | point_in_time · Q1FY27 · Q1FY27 | |
| Volume Growth | -12.7% | -12.7% | yoy · Q1FY27 |
| Dahej Plant Revenue | ₹26 Cr | +62.5% | yoy · Q1FY27 · vs ₹16 Cr in Q1FY26 |
| Dahej Plant EBITDA | <₹1 Cr | +~+₹4 Cr | yoy · Q1FY27 · vs -₹3 Cr in Q1FY26 |
| Royalty Expense | ₹4 Cr | −significantly lower | yoy · Q1FY27 · vs prior year |
| Innovation Turnover Index (3-year) | 11.56% | point_in_time · Q1FY27 · contribution of last 3 years' introductions |
Guidance
FY27 revenue growth guidance cut to low single digits; Dahej plant revenue guided to ₹65 Cr with EBITDA negative ₹4-5 Cr; Nagpur formulation plant (₹200 Cr, 23,000 MTPA) expected operational by Q4FY28.
What management committed to
- [Dhanuka Agritech] will launch five new products consisting of one Liquid Fertilizer, three Fungicides, and one Herbicide in the upcoming months. — five new products (1 Liquid Fertilizer, 3 Fungicides, 1 Herbicide), upcoming months
- [The new Nagpur formulation plant] will be operational by April 2028 with a capacity of 23,000 metric tonnes per annum and an estimated outlay of up to Rs. 200 crores. — 23,000 MTPA capacity; up to Rs. 200 Cr outlay, Q4FY28
- [The Dahej plant] will achieve revenue of around Rs. 65 crores in FY27 with EBITDA of negative Rs. 4-5 crores. — Revenue ~Rs. 65 Cr; EBITDA -Rs. 4-5 Cr, FY27
- [Dhanuka Agritech] will deliver small single-digit revenue growth for FY27. — small single-digit, FY27
- [Dhanuka Agritech] will incur capex of around Rs. 100 crore plus on the Nagpur project in FY27-28. — Rs. 100 crore plus, FY28
- [Dhanuka Agritech] will win the GST case on molecule classification under the fertilizer category.
- [Dhanuka Agritech] will introduce two more nutrition biological category products in this financial year [FY27]. — two more nutrition biological category products, FY27
- [The third of three bio-stimulant products] will be launched by August end [2026]. — third bio-stimulant product, Q2FY27
Key themes
Monsoon deficit hits demand, guidance cut, new Nagpur plant
How the narrative shifted
- Monsoon deficit disrupts kharif demand: Management attributes the revenue miss and guidance cut primarily to a 40% June rainfall deficit that delayed sowing and compressed the herbicide window, framing it as a cyclical headwind.
- Nagpur automated formulation capacity: The new plant is positioned as a leap toward global-standard, low-dose, environment-friendly products with smaller pack sizes, reducing labour dependency and enabling future scale.
- Bio-stimulants regulatory tailwind: Regulatory tightening is expected to squeeze unorganized players; management is re-launching previously banned products and sees the category as a lever for market share gains.
- International Bayer product buildout: Global distribution for Iprovalicarb/Triadimenol is being established with initial customers onboarded and incorporation of entities in Brazil and Europe, though near-term revenue contribution is downplayed.
- Dahej plant underperformance persists: Dahej revenue guided lower than run-rate at ₹65 Cr, EBITDA breakeven remains elusive; management cites demand seasonality and avoids giving a profitability timeline.
- Portfolio mix shifting to low-dose products: The company is increasingly focusing on low-dose, potent, environment-friendly chemistries, which aligns with the Nagpur plant design and may improve farmer affordability and margins.
Operational commentary
- Delayed and deficient monsoon (40% rainfall deficit in June) severely impacted herbicide offtake, the dominant category in Q1, particularly in Rajasthan, Gujarat, MP, Maharashtra; some resowing occurred.
- FY27 top-line growth guidance cut to 'small single-digit' from earlier expectations, with Q2 also off to a slow start; the revision reflects monsoon impact and a cautious near-term outlook.
- New Nagpur formulation plant announced: land acquired in Butibori industrial area, ₹200 Cr outlay, 23,000 MTPA capacity; designed as a highly automated facility focusing on low-dose, environment-friendly small-pack products; operational by April 2028 with CGST benefits from Maharashtra government.
- Dahej chemical synthesis plant doubled revenue YoY to ₹26 Cr but remains sub-scale; full-year FY27 revenue guided at ₹65 Cr with EBITDA negative ₹4-5 Cr; breakeven still difficult.
- Bayer-acquired global products (Iprovalicarb, Triadimenol) gaining traction: initial customers onboarded, Executive Director visiting US/Brazil; India Bayer revenue negligible in Q1 due to grape season timing (peak in Q2).
- Bio-stimulants re-launch underway: two of three previously banned products re-introduced, third by August-end; two additional nutrition-biological products planned in FY27; regulatory tightening seen favouring organized players.
- Five new product launches planned in coming months (1 liquid fertilizer, 3 fungicides, 1 herbicide), refreshing the growth pipeline.
- Inventory levels at distributors/retailers normal; no stocking or destocking trends observed; primary and secondary sales broadly aligned.
- GST notice on molecule classification contested via Lakshmikumaran; management expresses high confidence of winning, with the matter under consideration.
Analyst Q&A
Q. What revenue contribution from Bayer-acquired products (Iprovalicarb/Triadimenol) in FY27?
As of now, we are not sharing the number... But yes, we will address this query separately.
Q. What asset turns can be expected from the new Nagpur formulation plant given the ₹200 Cr capex appears high?
I think so this is probably not the right time for me to comment on the asset turns part, but I think we will be able to come back and address this once the project details and everything are deeply finalized, which is probably late Q4.
Q. What kind of revenue are you expecting from bio-stimulants in FY27?
Since we are almost reworking the bio-stimulant category... we are kind of reworking that and probably give you more details later.
Q. Why was there an 11% growth in Fungicides during Q1 which is typically a herbicide-heavy quarter?
A very special Japanese Fungicide has a special traction in dry season in horticulture crops. High horticulture prices gave traction for Nissodium and Conika.
Q. Are we confident the GST order will be in our favour?
Sure. Now these molecules are categorized under that category of fertilizer. Currently, as per the circular, it is 5%. We are sure we will win the case, absolutely. There's no doubt about it.
Q. How did Q1 pan out given price increases and low-cost inventory benefits, and how is Q2 looking?
Herbicides took a hit due to rainfall deficits... July has done better than June, yet what we see is a difficult quarter.
Research and educational content only. Not investment advice.